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Abstract
In the general population, obesity is associated with increased cardiovascular risk and decreased 
survival. In patients with end-stage renal disease (ESRD), however, an “obesity paradox” or 
“reverse epidemiology” (to include lipid and hypertension paradoxes) has been consistently 
reported, i.e. a higher body mass index (BMI) is paradoxically associated with better survival. 
This survival advantage of large body size is relatively consistent for hemodialysis patients across 
racial and regional differences, although published results are mixed for peritoneal dialysis 
patients.. Recent data indicate that both higher skeletal muscle mass and increased total body fat 
are protective, although there are mixed data on visceral (intra-abdominal) fat. The obesity 
paradox in ESRD is unlikely to be due to residual confounding alone and has biologic plausibility. 
Possible causes of the obesity paradox include protein-energy wasting and inflammation, time 
discrepancy among competitive risk factors (undernutrition versus overnutrition), hemodynamic 
stability, alteration of circulatory cytokines, sequestration of uremic toxin in adipose tissue, and 
endotoxin-lipoprotein interaction. The obesity paradox may have significant clinical implications 
in the management of ESRD patients especially if obese dialysis patients are forced to lose weight 
upon transplant wait-listing. Well-designed studies exploring the causes and consequences of the 
reverse epidemiology of cardiovascular risk factors, including the obesity paradox, among ESRD 
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patients could provide more information on mechanisms. These could include controlled trials of 
nutritional and pharmacologic interventions to examine whether gain in lean body mass or even 
body fat can improve survival and quality of life in these patients.
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Introduction
Patients with end-stage renal disease (ESRD) who receive maintenance dialysis therapy 
have a significantly higher mortality rate (about 20% per year in the United States and 10 – 
15% in Europe), primarily due to cardiovascular disease (CVD) [1, 2]. Based on 
extrapolation of findings from the general population, treatment to reduce cardiovascular 
morbidity and mortality has focused on conventional risk factors, such as obesity, 
hypertension and hypercholesterolemia. However, survival has not improved substantially in 
the past 3 decades. Additional efforts have targeted other possible correlates of the high 
mortality associated with ESRD, such as anemia or dialysis dose. However, large clinical 
trials have failed to show any survival advantages of normalization of hemoglobin level [3] 
or increasing dialysis dose in hemodialysis (HD) [4] and peritoneal dialysis (PD) [5].
A number of epidemiologic studies with large samples of ESRD patients have indicated 
paradoxically inverse associations between classic risk factors for CVD and mortality [6]. In 
terms of obesity, worse survival has been observed with a lower body mass index (BMI), 
and findings have also indicated that higher values of BMI reflecting overweight or obesity 
seemed to be associated with better survival (Figure 1). This phenomenon has been referred 
to as the obesity paradox. This term may not necessarily mean that the principles of vascular 
pathophysiology are different in ESRD patients compared to the general population but may 
indicate that there are other superimposed and more dominant factors that overwhelm the 
traditional relation between obesity and outcomes as seen in the general population.
A better understanding of the phenomenon of the obesity paradox in ESRD patients may 
help improve the poor outcomes in this population. In addition to earlier observations, recent 
studies have indicated the presence of the obesity paradox in contemporary cohorts across 
different races and geographic regions. In this article, the inverse association of BMI and 
mortality in ESRD patients and several hypotheses to it are reviewed. The distinct effects of 
dialysis modalities (HD versus PD) on nutritional parameters, and studies conducted 
exclusively in PD patients were summarized separately.
Body size and mortality in HD patients
HD patients appear to have a lower BMI than age- and sex-matched control subjects from 
the general population [7]. In a matched analysis comparing the lipid profiles of 285 HD 
patients with those of 285 non-ESRD patients matched in a one-to-one fashion on age, sex, 
race, and diabetes, BMI was found to be significantly lower in the HD patients than in the 
control subjects (26.2 ± 6.0 compared with 31.5 ± 7.8, p < 0.001) [8]. A lower BMI was 
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consistently found to be a strong predictor of increased mortality. Unlike the general 
population, however, a higher BMI (overweight or obesity) was generally not associated 
with an increase in mortality risk [9–19]. In spite of recent advances in HD techniques and 
drug therapies, this phenomenon remains present in virtually all large contemporary cohorts 
[20–29]. Most studies have shown that the inverse association between BMI and mortality in 
HD patients is independent of demographics, co-morbidities and other nutritional markers, 
although because of methodological differences, only limited comparisons can be made . 
Important epidemiologic studies are summarized in Table 1. Because these are clinical 
studies that follow mortality prospectively in well-characterized patient populations, they are 
able to take into account the clinical characteristics of the patients such as severity of illness. 
However, the ability of this type of study to identify biological mechanisms or choose 
among possible explanations is inherently somewhat limited. The biological mechanisms 
could be investigated using other study designs, including randomized clinical trials. The 
first report came from the Diaphane collaborative study in France, which reported a 
paradoxical observation of a lack of increase in mortality with high BMI in HD patients [9]. 
This study included a cohort of 1,453 younger, mostly non-diabetic French HD patients 
followed between 1972 and 1978 in 33 French dialysis units. Leavey et al [10] confirmed 
the lack of association between higher BMI values and increased mortality risk in a national 
sample of 3,607 HD patients in the United States Renal Data System (USRDS). The mean 
BMI was 24.4 ± 5.3 in this study. Low BMI was independently and significantly predictive 
of increased mortality. With the use of time-varying effect models, it was observed that the 
greatest predictive value of BMI occurred early during the follow-up period but its 
independent predictive ability for mortality risk persisted even 5 years later. No significant 
interactions were identified between BMI and other demographic, co-morbid conditions or 
laboratory variables. Fleischmann et al.[11] reported higher survival rates for overweight 
and obese HD patients (BMI ≥27.5) than for patients with a normal BMI of 20.0 – <27.5. 
This suggested for the first time that obesity might be protective in this population. The 
result also showed that for every unit increase in BMI, the relative risk of mortality was 
reduced by 10%.
Thereafter, the obesity paradox was replicated in various large, nationally representative or 
international cohorts. Kopple et al. [12] evaluated 12,965 HD patients and found that in both 
men and women, the mortality rate decreased progressively as the patients' weight-for-
height increased even after adjusting for clinical characteristics and laboratory 
measurements. These findings suggest that besides BMI other measures of body size also 
correlate inversely with mortality in maintenance HD patients. Port et al [16] analyzed data 
from 45,967 incident HD patients who started dialysis treatment between 1997 and 1998. Of 
the three body-size groups, the lowest BMI group had a 42% higher mortality risk compared 
to the highest BMI tertile. Similarly, Lowrie et al [17] analyzed survival in 43,334 HD 
patients treated on January, 1999 in different Kt and body-size groups defined by body 
weight, weight adjusted statistically for height, body surface area, weight divided by height, 
and BMI. The observed log-risk relationships were "reverse J-shaped" for weight divided by 
height and BMI. However, mortality risk was slightly increased only in patients with morbid 
obesity, i.e. BMI ≥34. Main effect models from that study suggested improved survival with 
increasing Kt and all of the size measures. The Dialysis Outcome and Practice Patterns 
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Study (DOPPS) also helped us understand the effect of body size on mortality in ESRD 
patients. In 9,714 HD patients in the US and Western Europe from 1996 to 2000, an inverse 
BMI – mortality association was found in all subpopulations defined by continent, race, sex, 
severity of illness, age, smoking, and diabetic status [14]. Overall, a lower relative risk (RR) 
of mortality, as compared with a BMI of 23.0 – 24.9 kg/m2, was found for overweight (BMI 
25.0 – 29.9 kg/m2), mild obesity (BMI 30.0 – 34.9 kg/m2) and moderate obesity (BMI 35.0 
– 39.9 kg/m2) [RR 0.84, 0.73 and 0.76, respectively; all p-value <0.05]. Contrary to the 
investigators’ hypothesis that the obesity paradox may not exist in healthier ESRD patients, 
there was a survival benefit in healthy overweight patients that was even greater in obese 
patients. With the largest cohort of incident HD patients (n = 418,055, 4/1995 – 10/2000, 
USRDS), Johansen et al. [19] sought to clarify the relation between body size and outcomes, 
especially for patients with extremely high BMI and for alternative measures of adiposity. 
They found that high BMI was associated with increased survival over a 2-y average follow-
up time after adjustment for confounding factors, even at extremely high BMI levels. This 
result was observed for whites, African Americans, and Hispanics but not for Asians. 
Alternative estimates of adiposity, including the Benn index and estimated fat mass, yielded 
similar results. Adjustments for lean body mass did not substantially alter the findings.
The obesity paradox in HD patients has been consistently observed in more contemporary 
cohorts. Kalantar-Zadeh et al. [20] explored the effect of both baseline BMI and change in 
BMI over time on cardiovascular mortality in a 2-year non-concurrent cohort of 54,535 HD 
patients in the US. They found that there were survival advantages of obesity for BMI cutoff 
values of 25, 30, and 35 across almost all strata of age, race, sex, dialysis dose, protein 
intake, and serum albumin level. Examining the regression slope of change in weight over 
time, progressively worsening weight loss was associated with poor survival, whereas 
weight gain showed a tendency toward decreased cardiovascular death. Chazot et al. [21] 
conducted a prospective observational study of 5,592 incident HD patient in Southern 
Europe. Patients were included between January, 2000 and September 2005 and followed 
for 2.0 ± 1.6 years. Notably, the prevalence of diabetes was lower (27.7%) in this cohort. 
The categories of baseline BMI (underweight, normal range, overweight and obese) 
significantly were significantly associated with survival. Relative to the normal range, 
estimated hazard ratios (HR) and 95% confidence intervals (CI) were 1.14 (0.96 – 1.35) for 
underweight, 1 (reference) for normal weight, 0.74 (0.67 – 0.9) for overweight and 0.78 
(0.56 – 0.87) for obesity. Moreover, when compared to patients for whom body weight 
remained stable during the first year, survival was significantly lower in patients with a 
decrease in body weight (<-5.8% in 1 year). Molnar et al. [24] identified 14,632 HD patients 
waitlisted for kidney transplantation by linking the 6-year (7/2001–6/2007) national 
databases of a large dialysis organization and the Scientific Registry of Transplant 
Recipients. Dialysis patients on transplant waiting lists have indeed better survival than their 
nonlisted counterparts, which could be explained by the less severe comorbidities seen in 
waitlisted patients. Even in this selected population, each unit higher BMI was associated 
with a mortality HR of 0.96 (95% CI 0.95 – 0.97) in a time-dependent survival model. 
Compared to minimal (< ±1 kg) weight change over 6 months, those with 3 – <5 kg and ≥5 
kg weight loss had mortality HRs of 1.31 (1.14 – 1.52) and 1.51 (1.30 – 1.75), respectively.
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Although most of the studies showed the BMI – survival association to be independent of 
patients’ age, one recent study suggests that BMI may interact with age to predict long-term 
survival in dialysis patients. Hoogeveen et al. [27] prospectively investigated the extent to 
which the relation of BMI and mortality differs between younger (<65 years, n = 984)) and 
older (≥65 years, n = 765) dialysis patients. Baseline BMI was categorized as <20, 20 – 24 
(reference), 25 – 29, and ≥30. After adjustment for age, sex, smoking, comorbidities, and 
treatment modality, estimated HRs (95% CI) across incremental BMI categories were 2.00 
(1.30 – 3.07), 1 (reference), 0.95 (0.69 – 1.31), and 1.57 (1.08 – 2.28) for younger patients 
and 1.07 (0.76 – 1.52), 1 (reference), 0.88 (0.72 – 1.08), and 0.91 (0.66 – 1.27) for older 
patients, implying that obesity is a 1.7-fold (95% CI 1.1 to 2.9-fold) stronger risk factor in 
younger than older patients.
Another interesting issue is whether or not the obesity – mortality association may differ by 
race/ethnicity in ESRD patients. It is important to generalize the concept of the obesity 
paradox beyond racial and regional differences. Glanton et al. [18] performed a historical 
cohort study on 151,027 incident ESRD patients who had never received kidney 
transplantation. They found that obese patients had a higher 2-year survival after controlling 
for comorbidities and other potential risk factors. However, the relation was not uniform and 
was stronger in African Americans. Rick et al. [25] evaluated whether or not higher BMI is 
more strongly associated with lower mortality among blacks and Hispanics than among non-
Hispanic whites. In a 6-year (2001–2007) cohort of 109,605 HD patients including 39,090 
blacks, 17,417 Hispanics, and 53,098 non-Hispanic white HD outpatients, a higher BMI was 
associated with greater survival in all 3 racial/ethnic groups. However, Hispanic and black 
patients experienced higher survival gains compared with non-Hispanic whites across higher 
BMI categories. Hispanics and blacks in the BMI ≥40 category had the lowest estimated 
mortality hazard ratios (HR 0.57, 95% CI 0.49 – 0.68 and HR 0.63, 95% CI 0.58 – 0.70) 
compared with non-Hispanic whites in the BMI 23 – <25 group (reference). In earlier 
studies, Kaizu et al. [30] analyzed the association of BMI with long-term survival in 116 
non-diabetic Japanese HD patients who were monitored for up to 12 years. Patients with a 
BMI of less than 16.9 and more than 23.0 showed lower survival relative to patients with 
BMI of 17.0 – 18.9. They failed to show a survival advantage of obesity in HD patients; 
however, patients with a BMI <16.9 were observed to have the highest risk of mortality, 
independent of age, gender, smoking, duration of HD, serum albumin, blood pressure and 
urea reduction rate. Johansen et al. [19] also reported that high BMI was not robustly 
associated with better survival in American Asians unlike whites, African Americans, and 
Hispanics. However, Yen et al. [23] examined 959 Taiwanese patients undergoing 
maintenance HD in a 3-year, multicenter longitudinal study. After three years, 149 (15.5%) 
patients had died. The mortality percentages were 21.6% in underweight (BMI <18.5), 
13.0% in normal weight (BMI 18.5 – 22.9), 20.3% in overweight (BMI 23.0 – 24.9), and 
15.5% in obese patients (BMI ≥25). Although they could not detect an inverse and linear 
relationship between BMI and mortality, BMI <18 was independently associated with 
increased mortality compared with BMI ≥25 in a multivariate regression model (HR 2.23, 
95% CI 1.22 – 4.05). Most recently, Park et al. [29] conducted analyses to determine 
whether the association of body size with survival among patients undergoing long-term HD 
is consistent across different races, especially in East Asian versus white and African 
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American patients. Using national data for 20,818 patients from South Korea who 
underwent HD from February 2001 to June 2009 and 20,000 matched patients from the US 
(10,000 whites and 10,000 African Americans), they found that BMI level was inversely and 
linearly associated with mortality even in East Asian HD patients (Figure 2); furthermore, 
the associations between BMI and mortality were very similar in all 3 races. They concluded 
that race does not modify the association of higher body size with greater survival, and the 
obesity paradox is a universal phenomenon irrespective of race in HD patients.
Body size and mortality in PD patients
Similar inverse associations between body size and mortality have been observed in some 
studies with PD patients, but a survival advantage associated with large body size seemed to 
be less likely in PD than HD patients [31] (Table 2), although comparisons are limited by 
methodological differences across studies, including the use of different BMI categories. In 
the Canada-USA (CANUSA) Peritoneal Dialysis Study Group, 1% lower lean body mass 
estimated from creatinine kinetics was associated with a 3% increase in the RR of death [32, 
33]. Chung et al. [34] described a similar association between lean body mass and mortality 
in Korean PD patients. Snyder et al. [35] conducted a retrospective cohort study with US 
Medicare patients initiating dialysis between 1995 and 2000 (n = 418,021), in which 41,197 
PD patients were included (11%). Among PD patients, adjusted mortality HR in the first, 
second, and third year were 1.45 (P < 0.05), 1.28 (P < 0.05), and 1.17 respectively for the 
underweight (BMI <18.5); 0.84 (P < 0.05), 0.89 (P < 0.05), and 0.98 respectively for the 
overweight (BMI 25.0 – 29.9); and 0.89 (P < 0.05), 0.99, and 1.00 respectively for the obese 
(BMI ≥30.0). These results were similar after considering switch to HD and transplantation. 
The investigators concluded that overweight and obese PD patients have longer survival 
than those with lower BMI and that this was not adequately explained by lower 
transplantation and technique survival rates.
McDonald et al. [36] performed an analysis of all incident adult ESRD patients (n = 9,679) 
who underwent an episode of PD treatment in Australia or New Zealand between April, 
1991 and March, 2002. In multivariate analyses, obesity (BMI ≥30 kg/m2) was 
independently associated with death (HR 1.36, 95% CI 1.14 – 1.54) and technique failure 
(HR 1.17, 95% CI 1.07 – 1.26), except among patients of New Zealand Maori/Pacific 
Islander origin, for whom there was no significant relationship between BMI and death. 
Fractional polynomial analysis modeled BMI as a continuous predictor and indicated a J-
shaped relationship between BMI and patient mortality rates. Abbott et al. [15] performed a 
retrospective cohort study with 1,675 HD and 1,662 PD patients included in the USRDS 
Dialysis Morbidity and Mortality Wave II Study. They found that among PD patients, 5-year 
survival for patients with BMI ≥30 was 38.7% vs. 40.4% for lower BMI (P > 0.05 by log-
rank test). In adjusted analysis, BMI ≥30 was associated with improved survival in HD 
patients (HR 0.89, 95% CI 0.81 – 0.99) but not in PD patients (HR 0.99, 95% CI 0.86 – 
1.15). Results were not different when censoring at change from PD to HD. Stack et al. [37] 
observed similar differences in the BMI – mortality association by dialysis modality in a 
cohort of 134,728 new ESRD patients who were initiated on dialysis from May, 1995 to 
July, 1997 using data from USRDS. For HD, the adjusted RR of death was greatest for 
patients in the lowest BMI quintile (≤ 20.9) and lowest for patients in the highest BMI 
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quintile (>30.0). For PD, the RR of death was higher for patients with a BMI <20.9 but no 
survival advantage was observed with higher BMI values compared with BMI of 23.5 – 
26.1. de Mutsert et al. [38] evaluated mortality associated with obesity in the PD population 
of the Netherlands Co-operative Study on the Adequacy of Dialysis-2 (NECOSAD-2) cohort 
(n = 688). Compared with a normal BMI (18.5 – 25.0), obesity at the start of PD (BMI ≥30) 
was associated with a HR of 0.8 (95% CI 0.5 – 1.3). Time-dependently, this was 0.7 (0.4 – 
1.2). The HR of BMI < 18.5 at the start of PD was 1.3 (95% CI 0.4 – 3.2), and time-
dependently this was 2.3 (1.0 – 5.3).
Body composition and mortality in ESRD patients
BMI may not be an optimal surrogate of visceral obesity when compared to waist 
circumference, which better reflects intra-abdominal (truncal) fat. Indeed Postorino et al. 
[39] showed that surrogate measures of abdominal obesity and segmental fat distribution 
(waist circumference and waist/hip ratio) were stronger predictors of all-cause and 
cardiovascular death than BMI in 537 patients with ESRD. In this study, higher BMI was 
protective whereas higher waist circumference was a predictor of higher mortality.[39] 
Interestingly, similar “crossing curves” have also been observed in elderly patients,[40] and 
in kidney transplant patients.[41]
Most large epidemiologic studies used BMI to define obesity. Although BMI has been 
accepted as one of the most reliable anthropometric indices for obesity and has been used 
widely in research and for guidelines on obesity, BMI has a limited ability to differentiate 
adiposity from muscle mass. However, assessing fat mass or muscle mass separately is 
particularly difficult in large epidemiologic studies and requires elaborate tests of body 
composition such as dual-energy X-ray absorptiometry (DEXA) [42]. For this reason, most 
studies have not examined the relative contribution of fat versus muscle mass or their 
changes over time to the survival benefits of larger body size.
Huang et al. [43] examined the relationship between measures of fat and muscle mass and 
mortality in 1,709 patients from the HEMO Study (median follow-up 2.5 years). Triceps 
skin-fold thickness was used to assess body fat and mid-arm muscle circumference was used 
to assess muscle mass. In adjusted models, higher BMI and higher triceps skin-fold 
thickness were significantly associated with decreased hazards of mortality, while higher 
mid-arm muscle circumference showed a trend toward decreased mortality. Noori et al. [44] 
tested the hypothesis that both higher fat mass (FM) and higher lean body mass (LBM) are 
associated with greater survival in HD patents irrespective of sex. In 742 HD patients, they 
categorized men (n = 391) and women (n = 351) separately into 4 quartiles of near-infrared 
interactance-measured FM and LBM. After adjustment for case-mix and inflammatory 
markers, the highest quartiles of FM and LBM were associated with greater survival in 
women: estimated HRs of 0.38 (95% CI 0.20 – 0.71) and 0.34 (95% CI 0.17 – 0.67), 
respectively (reference: first quartile). In men, the highest quartiles of FM but not of LBM 
were associated with greater survival: estimated HRs of 0.51 (95% CI 0.27 – 0.96), and 1.17 
(95% CI 0.60 – 2.27), respectively. Kalantar-Zadeh et al. [22] evaluated whether dry weight 
gain accompanied by an increase in muscle mass is associated with a survival benefit in HD 
patients. Serum creatinine concentration was used as a surrogate for muscle mass. Among 
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50,831 patients, those who gained weight and had an increase in serum creatinine 
concentration showed the best survival. Notably, those who lost weight but had an increased 
serum creatinine level had a greater observed survival rate than those who gained weight but 
had a decreased creatinine level. These findings may suggest that discordant muscle gain 
with weight loss over time confers more survival benefit than weight gain while losing 
muscle. The same research group also analyzed the relative role of muscle mass in the 
obesity paradox using a ranking analysis of joint effects in which the sums and differences 
of the percentiles of change for the 2 measures (weight and serum creatinine) in each patient 
were used as the regressors [28]. Concordant with previous observations, lower BMI, lower 
muscle mass, weight loss, and serum creatinine decline were associated with higher death 
rates. Among patients with a discordant change, persons whose weight declined but whose 
serum creatinine levels increased had lower death rates than those whose weight increased 
but whose serum creatinine level declined. These results suggest that some of the increased 
mortality in HD patients with lower BMIs might be explained by a lower muscle mass.
In PD patients, Ramkumar et al. [45] evaluated survival with BMI and 24-hr urinary 
creatinine excretion as a measure of muscle mass (n = 10,140). Patients with high BMI 
(≥25.0) but low muscle mass (24-hr urinary creatinine <0.64 g/day) might be considered to 
have high body fat mass. Compared to normal BMI – normal/high muscle mass patients, 
high BMI – normal/high muscle mass patients had lower hazard of cardiovascular (HR 0.88, 
95% CI 0.79 – 0.97) death; high BMI patients with low muscle mass had higher hazard of 
cardiovascular (HR 1.21, 95% CI 1.06 – 1.39) death. The authors concluded that both body 
size and body composition influence survival of incident PD patients and that PD patients 
should be encouraged to gain muscle mass rather than fat mass. For now, the relative 
influence of fat mass or muscle mass on the obesity paradox is difficult to evaluate because 
of limited epidemiologic evidence, unclear mechanistic processes to explain the obesity 
paradox and lack of hard evidence from nutritional or fitness trials..
Possible Explanations for the Obesity Paradox
The obesity paradox has been also observed in other populations such as the elderly [46] and 
in patients with congestive heart failure [47, 48]. The obesity paradox may appear 
counterintuitive, because obesity is an established risk factor for cardiovascular disease and 
poor outcomes in the general population. Indeed, it is not only lack of an association 
between obesity and mortality, but the opposite direction of this relation. Hence, there must 
be prevailing conditions that are uniquely present in ESRD patients, as well as in similar 
populations with a similar risk factor reversal. These conditions may render ESRD patients 
more susceptible to a poor outcome when BMI is low, and in whom obesity has a favorable 
effect on their future well-being. Several hypothetical explanations are briefly presented 
here.
1) Protein-energy wasting and inflammation—Usually, malnutrition refers to 
abnormalities induced by an inadequate diet, whereas wasting refers to abnormalities that 
cannot be corrected solely by increasing dietary intake [49, 50]. To avoid confusion 
regarding the terms and definitions used for conditions associated with loss of muscle and 
fat tissue, malnutrition, and inflammation in patients with chronic kidney disease (CKD), the 
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International Society of Renal Nutrition and Metabolism (ISRNM) expert panel 
recommended the term ‘protein-energy wasting (PEW)’ for loss of body protein and fuel 
reserves (that is, body protein and fat masses) [51]. Studies using classic measures of 
nutritional status indicate that wasting is frequently observed in ESRD patients [52, 53]. 
Recently, it has become apparent that PEW can be induced by inflammatory processes in 
ESRD patients [54–56]. Increased release or activation of inflammatory cytokines, such as 
interleukin-6 or tumor necrosis factor-α, may suppress appetite and may cause muscle 
proteolysis and hypoalbuminemia [57]. Moreover, loss of muscle and fat mass and 
inflammation are likely to increase the risk of death from cardiovascular or cerebrovascular 
disease, which is possibly mediated by promoting vascular endothelial damage [58–60]. On 
the other hand, it is possible, but not proven, that malnutrition may also predispose to 
inflammatory states as shown in animal models [61].
The obesity paradox in ESRD patients may be due to PEW and inflammation [6, 62]. 
Patients who have lower BMI or body weight may have PEW that is responsible for 
increased mortality. If overweight patients who have an increase in adipose tissue develop a 
deficiency in energy or protein intake, they would be less likely to develop frank PEW. In 
addition, it may be that when persons are malnourished, they are more susceptible to the 
ravages of inflammatory process [53, 63]. Hence, obesity may potentially attenuate the 
magnitude of PEW and/or inflammation, which would be favorable to ESRD patients.
The nutritional hypothesis may also explain why, in PD patients, the obesity paradox is less 
evident, i.e. the so-called “paradox-in-paradox” [31]. Almost all PD patients use 1.5 – 4.25% 
of dextrose in their peritoneal dialysate, 45% of which is estimated to be absorbed. In 
contrast, HD patients are exposed to 1% of dextrose in their dialysate during the 4-h, thrice-
weekly dialysis. A higher caloric intake by peritoneal dialysate may attenuate a potential 
benefit of obesity to prevent PEW in PD patients compared with HD patients.
Another explanation similar to the PEW and inflammation hypothesis has been put forward 
by Lowrie et al. [64]. During inflammatory conditions or malnutrition, body protein stores 
are diverted to defend against inflammation and to repair injury. Thus, the increased body 
mass of overweight dialysis patients offers protection against or resources for responding to 
inflammation, infection, and subsequent CVD. This theory may explain the survival benefit 
of a high BMI or creatinine concentrations in ESRD patients who have low nutritional 
reserves.
2) Time discrepancies among competing risk factors—In the populations of most 
industrialized countries, overnutrition is a major risk factor for long-term cardiovascular 
mortality [65–67]. These are areas of the world where people have a greater life expectancy 
than do those in other parts of the world; hence, such populations are relatively healthy and 
live long enough to die of consequences of conventional cardiovascular risk factors. Studies 
of risk factors for cardiovascular mortality are essentially based on these long living 
populations. In contrast, in developing countries, which represent most of the world’s 
population, undernutrition is still a powerful determinant of poor clinical outcome, which 
leads to a shorter life expectancy [68]. Similarly, survival advantages that exist in obese 
ESRD patients may, in the short term, outweigh the harmful effects of obesity on CVD in 
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the long term. Because most ESRD patients on dialysis die within 5 years of commencing 
dialysis treatment [69, 70], the long-term effects of obesity as a conventional risk factor on 
future mortality may be overwhelmed by the short-term effects of undernutrition and/or 
inflammation. Indeed, it may be difficult to observe mortality improvement by treating 
obesity in ESRD patients, who have a short life expectancy, even when such a risk reduction 
is beneficial in the general population that has a normal life expectancy.
3) Other potential hypotheses—Obesity may be associated with better short-term 
hemodynamic stability. Many ESRD patients on dialysis have some degree of heart failure 
and/or fluid overload. Despite having similar pulmonary capillary wedge pressure and 
cardiac indices, overweight and obese patients with heart failure tend to have higher systolic 
blood pressure values [47].Thus, obese patients might better tolerate removal of large 
volumes of fluid during dialysis with lower likelihood of transient hypotension. This may 
mitigate heightened sympathetic and rennin-angiotensin activities [71] which are associated 
with a poor prognosis in heart failure and fluid overload such as ESRD patients [72]. 
Furthermore, transient hypotension and related myocardial stunning during the HD 
procedure has been recently highlighted as a possible cause of the extremely high 
cardiovascular mortality seen in these patients [73–75]. The latter could also explain why 
the obesity paradox is less evident in PD patients who are more hemodynamically stable 
than HD patients when removing excessive fluid from the body.
Altered cytokine profiles of obese patients may play a role in conferring survival advantage 
to obese patients. Adipose tissue produces adiponectins, as well as soluble tumor necrosis 
factor alpha (TNF-α) receptors. TNF-α is elevated in heart failure and ESRD patients and 
may contribute to cardiac injury through its pro-apoptotic and negative inotropic effects [60, 
76]. Increased soluble TNF-α receptor may play a cardioprotective role via neutralizing the 
adverse effect of TNF-α [77].
It is also possible that uremic toxins are more effectively sequestered when abundant 
adipose tissue is present. Weight loss and reduction in adipose tissue were reported to be 
associated with the imminent release of circulating lipophilic hexachlorobenzene and other 
chlorinated hydrocarbons [78]. This finding may provide one hypothesis for why body fat 
loss has been found to be associated with increased death risk in ESRD patients [79]. In 
addition, obese patients generally have higher lipid and lipoprotein concentration. Since 
lipopolysaccharide concentrations are increased in persons with fluid overload [80, 81] and 
lipoproteins bind lipopolysaccharides, it is possible that a richer pool of lipoproteins in 
obese patients effectively retards the deleterious effects of circulating endotoxin, i.e., 
inflammation and subsequent atherosclerosis [81].
4) Reverse causation—As mentioned above, it is possible that lower BMI is not a cause 
but a consequence of conditions that lead to poor outcomes in ESRD patients. This effect, 
sometimes called reverse causation, is a type of confounding that is a possible source of bias 
in epidemiologic studies that examine associations without considering the direction of the 
causal pathway. However, if clinical studies adequately took into account severity of illness 
and other clinical characteristics reverse causation would not explain a finding that obesity, 
including morbid obesity, is associated with better outcomes in ESRD patients.
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5) Survival bias—ESRD patients are a very small proportion of the general population 
who have undergone specific processes of selection and survival; hence, they may not 
represent the general population. The relation between obesity and outcomes may have been 
modified through this patient selection. There are over 20 million patients with CKD in the 
US [82], but the vast majority of CKD patients will not live long enough to reach ESRD to 
commence maintenance dialysis [83]. Beyond severe and complex comorbid conditions, 
CKD itself is an independent risk factor for greater morbidity and mortality, particularly 
from cardiovascular and cerebrovascular diseases [83–85]. This partially explains why only 
a small proportion of CKD patients develop ESRD. Some CKD patients who have survived 
to make up the ESRD population might be “exceptional individuals” who successfully 
survived the conventional (traditional) risk factors such as obesity, hypertension, 
hypercholesterolemia, hypercreatininemia, and hyperhomocysteinemia, which are often 
strongly present in CKD patients. Hence, the assumption that the epidemiology of 
cardiovascular risk factors is the same in dialysis-dependent populations as in the general 
population may be flawed, because survival bias, a form of selection bias, may heavily 
influence the epidemiologic constellations in ESRD patients [62, 86, 87].
Remaining questions and future studies
The obesity paradox of cardiovascular mortality in ESRD patients may have indeed serious 
clinical and public health implications. Is the survival advantage of obesity in ESRD patients 
a clinically valid characteristic, or is it a statistical fallacy that needs to be ‘controlled 
away’? [88] Does obesity which promotes atherosclerosis and mortality in the general 
population, prevent cardiovascular death in ESRD patients and, if so, how? Should ESRD 
patients be advised to increase their nutrient intake to gain weight? In which subgroups of 
ESRD patients is obesity more protective than in others?
Studies presented above indicate that a higher BMI is associated with reduced mortality in 
these vulnerable populations. This phenomenon has been consistently observed in ESRD 
cohorts from the 90’s through the new millennium. Furthermore, this phenomenon does not 
differ by race or by region, which suggests that the concept of obesity paradox can be 
generalized. However, it is prudent to avoid causal inferences from such observational data 
until crucial clinical trial information is available. It is possible that overweight patients with 
ESRD suffer from more cardiovascular consequences if they survive long enough (time 
discrepancy hypothesis). Considering that overall mortality has not been much improved 
despite recent advances in dialysis techniques and drugs [70], a long-term longitudinal study 
is still hard to conduct.
Efforts to gain a better understanding of the existence, etiology, and components of the 
obesity paradox and the role of PEW and inflammation in its development in ESRD patients 
could provide useful information. It may be possible to identify the predominant risk factors 
responsible for extremely poor outcomes in ESRD patients, especially markers of PEW and 
inflammation. These nutritional or inflammatory states may be potentially modifiable, 
possibly resulting in improvement of clinical outcomes. This possibility has not yet been 
tested in randomized prospective clinical trials. In addition, a well-designed epidemiologic 
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study could provide insights about the mechanisms through which PEW and/or 
inflammation are associated with poor outcomes in ESRD patients.[89]
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Association of baseline BMI with mortality in 121,762 US HD patients over 5 years (July 
2001–June 2006). The y-axis shows the hazard ratio for all-cause mortality over 5 years 
based on the spline model (log scale), adjusted for age, sex, DM, dialysis vintage, primary 
insurance, marital status, dialysis dose, residual renal function, hemoglobin, serum albumin, 
transferrin, ferritin, calcium, phosphorus, bicarbonate, peripheral white blood cell count, 
lymphocyte percentage, and daily protein intake. Dashed lines are 95% point-wise 
confidence bands.
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Unadjusted and adjusted hazard ratios and 95% confidence intervals for all-cause mortality 
associated with BMI in 20,818 Korean HD patients. The model was adjusted for case-mix 
(age, sex, DM, dialysis history, dialysis dose, hemoglobin) and nutritional (serum albumin, 
and daily protein intake) covariates.
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Table 1
Summary of studies with large sample size (>1000 subjects) evaluating the association between BMI and 




Degoulet et al, 1982 [9] 1,453
HD
5 Lower BMI (<20 kg/m2) was associated with higher
over-all and CV mortality
Leavey et al, 1998 [10] 3,607
HD
5 Low BMI was independently predictive of increased
mortality.
Fleischmann et al, 1999 [11] 1,346
HD
1 Survival was significantly higher with higher BMI and
lower with lower BMI. Mostly African American
(89%)
Kopple et al, 1999 [12] 12,965
HD
1 Mortality rate decreased progressively as the patients'
weight-for-height increased.
Wolfe et al, 2000 [13] 9,165
HD
2 Body weight and BMI were inversely related to
mortality.
Leavey et al, 2001 [14] 9,417
HD
4 Mortality risk decreased with increasing BMI
independent of the degree of sickness
Port et al, 2002 [16] 45,967
HD
2 The highest BMI tertile had the lowest mortality risk.
Lowrie et al, 2002 [17] 43,334
HD
1 The log of risk decreased linearly for weight, weight-
for-height, and BSA and J-shaped for weight/height
and BMI.
Glanton et al, 2003 [18] 151,027
HD & PD
2 Obesity defined as BMI ≥30 kg/m2 was associated with
reduced mortality, which was stronger in African
Americans.
Johansen et al, 2004 [19] 418,055
HD & PD
2 High BMI, adiposity, and fat mass were associated
with increased survival in all but Asian Americans.
Kalantar-Zadeh et al, 2005 [20] 54,535
HD
2 Time-varying BMI and weight gain over time were
associated with improved cardiovascular mortality.
Chazot et al, 2009 [21] 5,592
HD
2 Overweight and obese patients carry a significant lower
mortality risk than patients in the normal and lower
BMI ranges. Low prevalence of DM (27.7%).
Kalantar-Zadeh et al, 2010 [22] 121,762
HD
2 Higher BMI (up to 45) was incrementally associated
with greater survival. Weight loss or gain over time
exhibited a graded association with higher rates of
mortality or survival
Yen et al, 2010 [23] 959
HD
3 Underweight patients (BMI <18.5 kg/m2) suffer higher
mortality than other groups in Asian cohort.
Molnar et al, 2011 [24] 14,632
HD
2.5 Transplant-waitlisted patients with lower BMI and/or
unintentional weight loss have higher mortality.
Rick et al, 2011 [25] 109,605
HD
2 Survival advantage of high BMI is consistent across
whites, African American and Hispanics, in which
African American HD patients had the strongest
association.
Hall et al, 2011 [26] 21,492
HD & PD
- Larger body size was associated with lower mortality
among Pacific Islanders, Whites and most Asians.
Hoogeveen et al, 2012 [27] 1,749
HD & PD
6 Age-standardized mortality rate was 1.7 times higher in
obese younger patients (<65 yo) than those with
normal BMI. Younger patients with low or very high
BMI had a substantially elevated risk for death

















Kalantar-Zadeh et al, 2012 [28] 121,762
HD
2 Lower BMI, lower muscle mass, weight and muscle
loss over time were associated with higher death
rates. In joint effect analysis, a decline in muscle
mass estimated with serum creatinine appeared to be
a stronger predictor of mortality than did weight
loss.
Park et al, 2013 [29] 40,818
HD
6 Mortality risks were lower across higher BMI, which
was identical among Asian vs. white and African
Americans.
†
Mean or median duration of follow-up was presented according to the reports.
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Table 2
Summary of studies with large sample size (>500 subjects) evaluating the association between BMI and 
outcomes in PD patients
Study Patients F/U† (yr) Results
Snyder et al, 2003 [35] 41,197
PD
3 Overweight and obese PD patients have longer survival
than those with lower BMI. Adjusted for
transplantation rate & dialysis modality change.
McDonald et al, 2003 [36] 9,679
PD
17,973 py Obesity was associated with increased death and
technique failure, in which there was J-shaped
relationship between BMI and mortality rates.
Australia/New Zealand population.
Abbott et al, 2004 [15] 1,662
PD
5 Survival for patients with BMI ≥30 kg/m2 did not differ
from that for counterpart.
Stack et al, 2004 [37] 17,419
PD
1 Risk of death was higher for patients with a BMI <20.9
kg/m2 but no survival advantage was associated with
higher BMI values (reference: 23.5 – 26.1 kg/m2).
Ramkumar et al, 2005 [45] 10,140
PD
17,500 py Both body size (BMI) and muscle mass (24-h urinary
creatinine excretion) influenced survival. Patients
with high BMI and normal/high muscle mass had the
best survival
de Mutsert et al, 2009 [38] 688
PD
5 Obese patients do not have a worse survival compared
with patients with a normal BMI. Patients with a low
BMI have a twofold increased mortality risk.
†
Mean or median duration of follow-up or person-year (py) was presented according to the reports.
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